Les Tari

Les Tari's Title

Les Tari holds the esteemed position of Chief Scientific Officer. In this role, he oversees scientific research and development, guiding the company's strategic direction in drug discovery and development. His leadership and expertise are pivotal in advancing the organization's research initiatives and ensuring the scientific rigor of its projects.

Les Tari's Education and Expertise

Les Tari earned his B.Sc. in Chemistry and later obtained a Ph.D. in Chemistry and Structural Biology from the University of Manitoba. His academic background laid a strong foundation for his career in drug discovery and structural biology. With over 19 years of experience in both industry and academia, Tari has developed a deep expertise in early-stage drug discovery, structural genomics, and medical research.

Les Tari's Achievements

Throughout his illustrious career, Les Tari has made significant contributions to the field of drug discovery. He is an author or inventor on over 50 publications and patents, demonstrating his ability to innovate and advance scientific knowledge. His work has had a lasting impact on the fields of inflammation, oncology, and antibiotic discovery, reflecting his broad research interests and expertise.

Les Tari's Experience

Les Tari's professional journey includes key roles at several influential companies. At Trius Therapeutics, he held positions of increasing responsibility from 2007 until its acquisition by Cubist Pharmaceuticals in 2013. Prior to that, he co-founded and served as Director of Structural Biology at ActiveSight Inc., leading research efforts in inflammation and oncology. His career also includes a significant tenure at Syrrx Inc., where he was instrumental in developing the first industrial high-throughput structural genomics platform. Additionally, Tari's academic experience includes a role as an Alberta Heritage Foundation Scholar for Medical Research at the University of Calgary, focusing on antibiotic discovery.